Journal for ImmunoTherapy of Cancer (Nov 2023)

1173 GNUV205, a bifunctional protein of engineered IL-2 fused with a novel anti-PD1 antibody, exhibits superior tumor suppressing efficacy in vivo

Eunju Choi,
Jenny Choih,
Hak-Jun Jung,
Kwanghyun Lee,
Sungho Han,
Donggoo Bae,
Heungrok Park,
June Myoung Kim,
Hyun Soo Shin

Affiliations

Eunju Choi: 1Genuv Inc., Seoul, Republic of Korea
Jenny Choih: 1Genuv Inc., Seoul, Republic of Korea
Hak-Jun Jung: 1Genuv Inc., Seoul, Republic of Korea
Kwanghyun Lee: 1Genuv Inc., Seoul, Republic of Korea
Sungho Han: 1Genuv Inc., Seoul, Republic of Korea
Donggoo Bae: 1Genuv Inc., Seoul, Republic of Korea
Heungrok Park: 1Genuv Inc., Seoul, Republic of Korea
June Myoung Kim: 1Genuv Inc., Seoul, Republic of Korea
Hyun Soo Shin: 1Genuv Inc., Seoul, Republic of Korea

DOI: https://doi.org/10.1136/jitc-2023-SITC2023.1173
Journal volume & issue: Vol. 11, no. Suppl 1

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal